November 27, 2013 / 6:44 AM / 4 years ago

BRIEF-Galapagos to get 34 mln euro milestone payment from GSK

1 Min Read

BRUSSELS, Nov 27 (Reuters) - Galapagos NV : * GSK to initiate exploratory Phase 2 study with GSK2586184 in patients with

ulcerative colitis * Ulcerative colitis is a third indication for this investigational molecule,

in addition to psoriasis and lupus * To receive from GSK 34 mln euros, and up to double-digit royalties on commercial sales of GSK2586184

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below